1. Articles in category: Prognostics

    1-19 of 19
    1. Elevated Preoperative Neutrophil-Lymphocyte Ratio is Predictive of a Poorer Prognosis for Pediatric Patients with Solid Tumors.

      Elevated Preoperative Neutrophil-Lymphocyte Ratio is Predictive of a Poorer Prognosis for Pediatric Patients with Solid Tumors.

      Ann Surg Oncol. 2017 Jul 17;:

      Authors: Nayak A, McDowell DT, Kellie SJ, Karpelowsky J

      Abstract BACKGROUND: An elevated neutrophil-lymphocyte ratio (NLR) has been shown to indicate poorer prognosis for adults with solid tumors and potentially represents an independent, universal adjunct prognostic factor.

      Read Full Article
    2. Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.

      Neuroblastoma in children: Update on clinicopathologic and genetic prognostic factors.

      Pediatr Hematol Oncol. 2017 Jun 29;:1-21

      Authors: Ahmed AA, Zhang L, Reddivalla N, Hetherington M

      Abstract Neuroblastoma is the most common extracranial solid tumor in childhood accounting for 8-10% of all childhood malignancies. The tumor is characterized by a spectrum of histopathologic features and a heterogeneous clinical phenotype.

      Read Full Article
      Mentions: MYCN
    3. MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma.

      MYCN amplification predicts poor prognosis based on interphase fluorescence in situ hybridization analysis of bone marrow cells in bone marrow metastases of neuroblastoma.

      Cancer Cell Int. 2017;17:43

      Authors: Yue ZX, Huang C, Gao C, Xing TY, Liu SG, Li XJ, Zhao Q, Wang XS, Zhao W, Jin M, Ma XL

      Read Full Article
      Mentions: MYCN Bone Marrow LDH
    4. PD-L1 is a therapeutic target of the Bromodomain inhibitor JQ1 and, combined with HLA class I, a promising prognostic biomarker in neuroblastoma.

      PD-L1 is a therapeutic target of the Bromodomain inhibitor JQ1 and, combined with HLA class I, a promising prognostic biomarker in neuroblastoma.

      Clin Cancer Res. 2017 Mar 07;:

      Authors: Melaiu O, Mina M, Chierici M, Boldrini R, Jurman G, Romania P, D'Alicandro V, Benedetti MC, Castellano A, Liu T, Furlanello C, Locatelli F, Fruci D

      Read Full Article
      Mentions: MYCN PD-1
    5. Simple test predicts childhood cancer relapse

      Simple test predicts childhood cancer relapse

      Researchers at Brunel University London and University College London have pinpointed a protein marker, which when absent, shows neuroblastoma is almost certain to recur. It means children with low-risk neuroblastoma, who don’t have the biomarker called PML, can be reclassified as at high risk of relapse and have chemotherapy earlier. A cheap simple test could accurately predict the recurrence of a childhood cancer.

      Read Full Article
    6. Response Assessment in Paediatric Phase I Trials According to RECIST Guidelines: Survival Outcomes, Patterns of Progression and Relevance of Changes in Tumour Measurements

      RECIST guidelines constitute the reference for radiological response assessment in most paediatric trials of anticancer agents. However, these criteria have not been validated in children. We evaluated the outcomes and patterns of progression of children/adolescents enrolled in phase I trials in two paediatric drug development units.

      Read Full Article
    7. The Relationship Between Apoptotic Activity and Prognostic Factors in Neuroblastomas.

      The Relationship Between Apoptotic Activity and Prognostic Factors in Neuroblastomas.

      Turk Patoloji Derg. 2016;32(2):99-104

      Authors: Ekmekci S, Olgun N, Özer E

      Abstract OBJECTIVE: Prognostic parameters in determining risk groups for treatment in neuroblastoma are cellular differentiation, mitosis karyorrhexis index (MKI), N-myc amplification and age. However, additional prognosticators are still needed because patients can show unpredictable biological behavior.

      Read Full Article
    8. Prognostic significance of MCM 2 and Ki-67 in neuroblastic tumors in children.

      Prognostic significance of MCM 2 and Ki-67 in neuroblastic tumors in children.

      Postepy Hig Med Dosw (Online). 2015;69(0):1268-1274

      Authors: Lewandowska M, Taran K, Sitkiewicz A, Andrzejewska E

      Abstract INTRODUCTION: Neuroblastic tumors can be characterized by three features: spontaneous regression, maturation and aggressive proliferation. The most common and routinely used method of assessing tumor cell proliferation is to determine the Ki-67 index in the tumor tissue.

      Read Full Article
    9. Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

      Methyl-CpG-binding domain sequencing reveals a prognostic methylation signature in neuroblastoma.

      Oncotarget. 2015 Dec 6;

      Authors: Decock A, Ongenaert M, Cannoodt R, Verniers K, De Wilde B, Laureys G, Van Roy N, Berbegall AP, Bienertova-Vasku J, Bown N, Clément N, Combaret V, Haber M, Hoyoux C, Murray J, Noguera R, Pierron G, Schleiermacher G, Schulte JH, Stallings RL, Tweddle DA, Children’s Cancer and Leukaemia Group (CCLG), De Preter K, Speleman F, Vandesompele J

      Read Full Article
    10. WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.

      WT1 expression is inversely correlated with MYCN amplification or expression and associated with poor survival in non-MYCN-amplified neuroblastoma.

      Mol Oncol. 2015 Oct 15;

      Authors: Masserot C, Liu Q, Nguyen E, Gattolliat CH, Valteau-Couanet D, Bénard J, Huber C, Ségal-Bendirdjian E

      Read Full Article
      Mentions: MYCN
    11. Assessing the accuracy of death records and pre-mortem clinical diagnoses in children diagnosed with brain tumors: A retrospective chart review of children in British Columbia, Canada.

      (Brain Tumours) "A third of patients had discrepancies between pre-mortem and post-mortem clinical diagnoses, with slightly over 10% of these cases revealing information that would have altered the probability of survival had it been known prior to death. More than half (59.3%) of cases had discordant cause of death as recorded in the cancer registry when compared to autopsy findings. Autopsy for children diagnosed with a PBT can provide health care professionals with important information about the accuracy of their diagnoses and evaluate the efficacy of therapy."

      Read Full Article
      Mentions: Surgery
    12. Clinical Significance of Persistent Tumor in Bone Marrow during Treatment of High-risk Neuroblastoma.

      The records of 63 high-risk neuroblastoma patients with bone marrow (BM) tumors at diagnosis were retrospectively reviewed. All patients received nine cycles of induction chemotherapy followed by tandem high-dose chemotherapy and autologous stem cell transplantation (HDCT/auto-SCT).

      Read Full Article
    13. Phox2B correlates with MYCN and is a prognostic marker for neuroblastoma development.

      AbstractNeuroblastoma is the one of the most common extracranial childhood malignancies, accounting for ∼15% of tumor-associated deaths in children. It is generally considered that neuroblastoma originates from neural crest cells in the paravertebral sympathetic ganglia and the adrenal medulla. However, the mechanism by which neuroblastoma arises during sympathetic neurogenesis and the cellular mechanism that drives neuroblastoma development remains unclear.

      Read Full Article
      Mentions: MYCN PHOX2B
    14. Prognostic significance of MDM2 gene expression in childhood neuroblastoma.

      1Laboratory of Experimental Oncology, National Cancer Institute, Kyiv 03022, Ukraine. 2Pediatric Oncology Department, National Cancer Institute, Kyiv 03022, Ukraine. To investigate the association of MDM2 expression at the mRNA levels in neuroblastoma with clinical features and unfavorable disease factors to determine the possibility of it usage as a prognostic marker of neuroblastoma.

      Read Full Article
      Mentions: MYCN
    15. Comparison of RNA-seq and microarray-based models for clinical endpoint prediction.

      1BGI-Shenzhen, Main Building, Bei Shan Industrial Zone, Yantian District, Shenzhen, Guangdong, 518083, China. 2Collaborative Innovation Center for Genetics and Development, State Key Laboratory of Genetic Engineering and MOE Key Laboratory of Contemporary Anthropology, School of Life Sciences and School of Pharmacy, Fudan University, Shanghai, 201203, China. 3Department of Pediatric Oncology and Hematology, University Children's Hospital of Cologne, Kerpener Strasse 62 D-50924, Cologne, Germany.

      Read Full Article
    16. Clinical research on neuroblastoma based on serum lactate dehydrogenase.

      1Pediatric Department, Qilu Hospital of Shandong University, Jinan, China. 2Department of Gynaecology and Obstetrics, Affiliated Hospital of Shandong Academy of Medical Sciences, Jinan, China. 3Pediatric Department, Zibo Central Hospital, Zibo, China. In recent years, more and more scholars tend to study neuroblastoma (NB) since it possesses increasing morbidity, but lack of effective treatment.

      Read Full Article
      Mentions: LDH NSE
    17. CASC15-S is a tumor suppressor lncRNA at the 6p22 neuroblastoma susceptibility locus.

      Chromosome 6p22 was identified recently as a neuroblastoma susceptibility locus, but its mechanistic contributions to tumorigenesis are as yet undefined. Here we report that the most highly significant single nucleotide polymorphism (SNP) associations reside within CASC15, a long non-coding RNA that we define as a tumor suppressor at 6p22

      Read Full Article
    18. Augmented expression of MYC and/or MYCN protein defines highly aggressive MYC-driven neuroblastoma: a Children's Oncology Group study.

      BACKGROUND: MYCN amplification with subsequent MYCN protein overexpression is a powerful indicator of poor prognosis of neuroblastoma patients. Little is known regarding the prognostic significance of the homologous MYC protein expression in neuroblastoma.

      Read Full Article
      Mentions: COG MYCN
    1-19 of 19
  1. Categories

    1. Research:

      Cancer Cell, Case Report, Cells and Stem Cells, Clinical Research, Conferences, Disease Classification, Drug, Drug Delivery, Drug Resistance, Epigenetics and Epigenomics, General, Genetics, Genomics, Guidelines, Immune Therapy, Induction, Long Term Effects, Low / Intermediate Risk, Nanotechnology, Olfactory Neuroblastoma, Onco-Fertility, Oncogenesis, Other Cancers, Personalized Medicine, Pharma, Pre-Clinical, Prognostics, PubMed, Review, Small Molecules, Surgery, Survivorship, Trials, Tumor Biology, Virotherapy
    2. Business:

      Funding, IP, Pharma
    3. Non-Profit:

      Advocacy, Charity, Events, Foundation, Funding, Human Interest
    4. Press Release:

      Announcement, News, Pharma
    5. General:

      Adolescent and Young Adults, Bioethics, Blog, Burden of Treatment, Children & Families, Diagnosis and Detection, Drug Development, Epidemiology, Imaging, Incidence, Information, News, Overview of the Disease, Pain Control, Palliative Care, Psychosocial, Regulation, Side-Effects, Social, Supportive Care, Treatment
    6. Media:

      Audio, Blogs, Video
  2. Popular Articles